Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IFX-1 steroid-replacement study in active GPA and MPA
NL-OMON55826Phase 2Active, not recruiting
- Sponsor
- InflaRx
- Start
- Apr 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vilobelimab in granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) (2 arms), sponsored by InflaRx. Primary endpoint: Clinical response at Week 16. Started Apr 2019; status: active, not recruiting.
02
Drugs
vilobelimab
03
Conditions
granulomatosis with polyangiitis (GPA)microscopic polyangiitis (MPA)
Beyond the preview
Go deeper on NL-OMON55826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55826.